Clinical trials: Pancreatic Metastatic Cancer, open to volunteers
Metastatic Pancreatic Ductal Adenocarcinoma
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine-Abraxane or Gemcitabine monotherapy
- Trial name
- NALPAC (NCT05472259)
- Testing
- Nanoliposomal irinotecan, 5 FU, Leucovorin
- Where
- 13 sites in Belgium
- Volunteers
- 134 people
- Sponsor
- Belgian Group of Digestive Oncology
Pancreatic Cancer
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and…
- Trial name
- NCT06307080
- Testing
- Multi-mode thermal ablation device, Intravenous anti-PD-1 and chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in…
- Trial name
- NCT05859750
- Testing
- AK104, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Akeso
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma
- Trial name
- NCT03977233
- Testing
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Metastatic Pancreatic Ductal Adenocarcinoma
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT06904378
- Testing
- ONT01, Gemcitabine, Nab paclitaxel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
- Trial name
- NCT06941857
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe…
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Trial name
- PANGEA (NCT06483555)
- Testing
- Gemcitabine, Nab paclitaxel, Erlotinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Liver Metastases, Non-Small Cell Lung Cancer
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
This study aims to evaluate the effectiveness and safety of combining low-dose radiotherapy to the intestines with immune checkpoint inhibitors (ICIs) in patients with liver metastases from solid tumors.
- Conditions
- Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic
- Trial name
- ILDR-ICI-LM (NCT07875465)
- Testing
- Intestinal Low-Dose Radiotherapy (ILDR), PD-1/PD-L1 inhibitors, Combined Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bing Xia
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT04005690
- Testing
- Cobimetinib, Olaparib, Onvansertib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- OHSU Knight Cancer Institute
Tumor, Solid, Pancreatic Cancer
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.
- Conditions
- Tumor, Solid, Pancreatic Cancer, Melanoma
- Trial name
- NCT03454035
- Testing
- Ulixertinib, Palbociclib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Cancer, Pancreatic Cancer Metastatic
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- MAPKeeper 301 (NCT07562152)
- Testing
- Atebimetinib, GnP, mGnP
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 570 people
- Sponsor
- Immuneering Corporation
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05040360
- Testing
- Capecitabine, Temozolomide
- Where
- 448 sites in United States, Mexico and 1 more
- Volunteers
- 141 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine…
- Trial name
- NCT06639724
- Testing
- Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Diego
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC)
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DFC413, and in Part 2 compare to [68Ga]Ga-NNS309 in patients with locally advanced or…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
- Trial name
- NCT07630961
- Testing
- 68Ga-DFC413, 68Ga-NNS309
- Where
- 2 sites in Denmark, Japan
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT06648434
- Testing
- Zunsemetinib, mFOLFIRINOX
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Solid Tumor
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05732831
- Testing
- TNG462, Pembrolizumab
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 225 people
- Sponsor
- Tango Therapeutics, Inc.
Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
This is a prospective, single-center, randomized, open-label, two-arm Phase II clinical trial design to evaluate the feasibility, safety and preliminary efficacy of combining fecal Fecal Microbiota Transplantation （FMT） Combined…
- Trial name
- NCT07845565
- Testing
- FMT+Chemotherapy+Immunotherapy, Chemotherapy+Immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital